Avista Therapeutics' mission is to develop innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on patients' quality of life. We ...

The Supreme Court on Wednesday morning heard oral argument in the consolidated cases of Oklahoma Statewide Charter School Board v. Drummond and St. Isidore of Seville School v. Drummond ...

NATICK, Mass., April 28, 2025 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy ...

Late-Breaker Presentation Details Presentation Title: A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal ...

The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global ...

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative ...

The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global ...

We look forward to sharing an oral presentation on a lisaftoclax combination regimen in patients with treatment-naïve or prior venetoclax-exposed myeloid malignancies and a readout on ...

Candel Therapeutics announced an oral presentation of CAN-2409 data at the ASCO Annual Meeting, focusing on prostate cancer treatment. Candel Therapeutics, Inc. announced the acceptance of an ...

Full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET. Oral Presentation Title: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients ...